Wells Fargo’s Indaptus Therapeutics INDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2
| Closed | -$21 | – | 7235 |
|
|
2025
Q2 | $21 | Hold |
2
| – | – | ﹤0.01% | 6773 |
|
|
2025
Q1 | $35 | Hold |
2
| – | – | ﹤0.01% | 6525 |
|
|
2024
Q4 | $54 | Hold |
2
| – | – | ﹤0.01% | 6489 |
|
|
2024
Q3 | $79 | Hold |
2
| – | – | ﹤0.01% | 6306 |
|
|
2024
Q2 | $136 | Sell |
2
-2
| -50% | -$133 | ﹤0.01% | 6224 |
|
|
2024
Q1 | $235 | Hold |
4
| – | – | ﹤0.01% | 6452 |
|
|
2023
Q4 | $183 | Hold |
4
| – | – | ﹤0.01% | 6633 |
|
|
2023
Q3 | $281 | Hold |
4
| – | – | ﹤0.01% | 6499 |
|
|
2023
Q2 | $193 | Hold |
4
| – | – | ﹤0.01% | 6711 |
|
|
2023
Q1 | $183 | Hold |
4
| – | – | ﹤0.01% | 6796 |
|
|
2022
Q4 | $142 | Buy |
4
+1
| +33% | +$51 | ﹤0.01% | 6717 |
|
|
2022
Q3 | $0 | Sell |
3
-1
| -25% | -$78 | ﹤0.01% | 6973 |
|
|
2022
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 7121 |
|
|
2022
Q1 | $0 | Sell |
4
-10
| -71% | -$1.28K | ﹤0.01% | 7412 |
|
|
2021
Q4 | $2K | Buy |
14
+12
| +600% | +$2.23K | ﹤0.01% | 6884 |
|
|
2021
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 7225 |
|
|
2021
Q2 | $1K | Sell |
2
-27
| -93% | -$11.9K | ﹤0.01% | 6673 |
|
|
2021
Q1 | $14K | Buy |
29
+27
| +1,350% | +$14.2K | ﹤0.01% | 6250 |
|
|
2020
Q4 | $1K | Hold |
2
| – | – | ﹤0.01% | 6350 |
|
|
2020
Q3 | $1K | Hold |
2
| – | – | ﹤0.01% | 6210 |
|
|
2020
Q2 | $1K | Hold |
2
| – | – | ﹤0.01% | 6174 |
|
|
2020
Q1 | $1K | Hold |
2
| – | – | ﹤0.01% | 6063 |
|
|
2019
Q4 | $3K | Hold |
2
| – | – | ﹤0.01% | 6119 |
|
|
2019
Q3 | $4K | Buy |
+2
| New | +$5.95K | ﹤0.01% | 6106 |
|
|
2019
Q1 | – | Hold |
0
| – | -$8K | – | 6239 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 5980 |
|
Other funds holding INDP
VF
TRCT
SS
Wells Fargo's INDP Position: Q3 2025 in Review
Wells Fargo sold out of Indaptus Therapeutics (INDP) in Q3 2025, closing a stake of 2 shares — an estimated $21 sold.
Wells Fargo first reported a position in INDP in Q3 2019 and held it in 24 quarters. The position peaked at $14K in Q1 2021. 5 funds tracked by Wall St. Rank hold INDP as of Q3 2025.
- Wells Fargo reported no remaining Indaptus Therapeutics position as of Q3 2025 after selling out during the quarter.
- Wells Fargo sold 2 Indaptus Therapeutics shares in Q3 2025, an estimated $21.
- Wells Fargo first reported a position in Indaptus Therapeutics in Q3 2019 and held it in 24 quarters.
- Wells Fargo's Indaptus Therapeutics position peaked at $14K in Q1 2021.
- 5 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2025.
Based on Wells Fargo's 13F filing for Q3 2025, filed 13 Nov 2025.